Navigation Links
German Patient Surpasses 5 Years of Support on DuraHeart™ Left Ventricular Assist Device
Date:7/19/2011

ANN ARBOR, Mich., July 19, 2011 /PRNewswire/ -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced that a patient implanted with the DuraHeart™ Left Ventricular Assist System (LVAS) has surpassed five years of support on the mechanical circulatory support device.  Helga Gieseke, living in Germany, was treated at The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute Berlin) and is now one of the longest-living heart failure recipients of the DuraHeart™ LVAS device.  

"Now I can breathe again...for years before I received the DuraHeart I was unable to do anything with my children or grandchildren. Since the DuraHeart, I was able to experience the birth of my little grandchild...I can now do things like walk and play catch and am able to participate in the lives of my family."

Mrs. Gieseke's heart problems have been occurring since the 1980's; her first heart surgery was performed in 1994. Between 1994 and 2006, Mrs. Gieseke underwent several procedures including implantation of stents, pacemakers and implantable defibrillators in an attempt to manage her condition. Despite all these treatments, Mrs. Gieseke's condition continued to deteriorate until she found herself unable to walk or carry out simple activities without experiencing chest pain and being short of breath.

Mrs. Gieseke admits that without the DuraHeart, she would probably not have lived to see her most recent birthday. "DuraHeart was my only option; there is a shortage of donor organs, and DuraHeart was my last chance. My family supported my decision {to implant an investigational device} and we have all been extremely happy with the decision and the quality of life the DuraHeart has afforded me."

"It is so gratifying to see patients such as Mrs. Gieseke who have been able to proceed with their lives following the implantation of the DuraHeart LVAS," says President and CEO of Terumo Heart, William Pinon. "Mrs. Gieseke is a prime example of how someone who was in declining health can lead a fulfilling life with end stage heart failure."

The DuraHeart LVAS is the latest-generation rotary blood pump designed for long-term patient support.  The system incorporates a centrifugal flow rotary pump with the magnetically levitated impeller. The pump features three position sensors and electromagnetic coils that suspend the impeller inside the pump chamber without a single contact point. The impeller's active magnetic levitation is designed to eliminate friction by allowing a wide gap between blood contacting surfaces, enabling blood to flow through the pump unimpeded in a smooth, non-turbulent fashion.

The DuraHeart LVAS carries a CE Mark and is currently available for sale in Japan and Europe.  DuraHeart is limited to investigational use only in the United States.  For more information about heart failure, Ventricular Assist Devices or the DuraHeart LVAS, visit www.terumoheart.com.

About Heart Failure

More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization.  The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transplants annually, but less than 3,000 receive a transplant each year.  A large number of people who suffer from severe heart failure do not qualify for transplantation due to other health issues. An alternative for these patients is access to artificial mechanical assist.

About Terumo Heart, Inc.

Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan.  The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients.  Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe.  For more information visit www.terumoheart.com


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008
5. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
6. Award-Winning Medical Technology From Germany
7. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
8. Enigma Diagnostics Showcases Its Unique Fully Automated rtPCR Based ML (Mini-Laboratory) Instrument For Point-of-Care Testing at MEDICA 2009 In Dusseldorf, Germany
9. Tekia Enters Into Distribution Agreement With Fritz Ruck/T-MED, Germany to Market Its Accommodative Intraocular Lens to Treat Presbyopia
10. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
11. German District Court Finds RENASYS™ GO NPWT System Non-infringing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... Miami native and local periodontist Dr. John Paul ... never imagined back in 1991 that this journey would have taken me into so ... 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... agile ecosystem and domain expertise for sponsors and CROs to speed clinical ... supply management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
Breaking Medicine News(10 mins):